231 related articles for article (PubMed ID: 37794090)
1. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
Shin WS; Han SH; Jo KW; Cho Y; Kim KT
Sci Rep; 2023 Oct; 13(1):16663. PubMed ID: 37794090
[TBL] [Abstract][Full Text] [Related]
2. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
[TBL] [Abstract][Full Text] [Related]
3. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
4. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
[TBL] [Abstract][Full Text] [Related]
5. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
6. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
8. Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer.
Gao K; Li X; Ni J; Wu B; Guo J; Zhang R; Wu G
Cancer Lett; 2023 Jul; 566():216247. PubMed ID: 37263338
[TBL] [Abstract][Full Text] [Related]
9. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
10. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
12. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
13. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
14. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
18. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
19. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
20. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
